Skip to main content
PMC home page
Journal of Medical Ethics logoLink to Journal of Medical Ethics
. 1999 Apr;25(2):209–214. doi: 10.1136/jme.25.2.209

Should we genetically test everyone for haemochromatosis?

K Allen 1, R Williamson 1
PMCID: PMC479209  PMID: 10226930

Abstract

The increasing availability of DNA-based diagnostic tests has raised issues about whether these should be applied to the population at large in order to identify, treat or prevent a range of diseases. DNA tests raise concerns in the community for several reasons. There is the possibility of stigmatisation and discrimination between those who test positive and those who don't. High-risk individuals may be identified for whom no proven effective intervention is possible, or conversely may test "positive" for a disease that does not eventuate. Controversy concerning prenatal diagnosis and termination of affected pregnancies may arise. Haemochromatosis, however, is a disease that is not only treatable but also preventable if those at high risk are identified presymptomatically. This paper will identify and discuss key issues regarding DNA-based population screening for haemochromatosis, and argue that population-based genetic screening for haemochromatosis should be supported when a number of contentious issues are addressed. In the context of a health system with limited resources haemochromatosis is the paradigm of a disorder where there is an ethical and clinical imperative to encourage presymptomatic DNA testing for all in ethnically relevant communities.

Full text

PDF
209

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams P. C., Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology. 1996 Apr;23(4):724–727. doi: 10.1002/hep.510230411. [DOI] [PubMed] [Google Scholar]
  2. Bacon B. R. Diagnosis and management of hemochromatosis. Gastroenterology. 1997 Sep;113(3):995–999. doi: 10.1016/s0016-5085(97)70196-3. [DOI] [PubMed] [Google Scholar]
  3. Bassett M. L., Leggett B. A., Halliday J. W., Webb S., Powell L. W. Analysis of the cost of population screening for haemochromatosis using biochemical and genetic markers. J Hepatol. 1997 Sep;27(3):517–524. doi: 10.1016/s0168-8278(97)80357-1. [DOI] [PubMed] [Google Scholar]
  4. Benkendorf J. L., Reutenauer J. E., Hughes C. A., Eads N., Willison J., Powers M., Lerman C. Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility. Am J Med Genet. 1997 Dec 19;73(3):296–303. doi: 10.1002/(sici)1096-8628(19971219)73:3<296::aid-ajmg13>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  5. Bulaj Z. J., Griffen L. M., Jorde L. B., Edwards C. Q., Kushner J. P. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med. 1996 Dec 12;335(24):1799–1805. doi: 10.1056/NEJM199612123352403. [DOI] [PubMed] [Google Scholar]
  6. Burke W., Press N., McDonnell S. M. Hemochromatosis: genetics helps to define a multifactorial disease. Clin Genet. 1998 Jul;54(1):1–9. doi: 10.1111/j.1399-0004.1998.tb03683.x. [DOI] [PubMed] [Google Scholar]
  7. Burke W., Thomson E., Khoury M. J., McDonnell S. M., Press N., Adams P. C., Barton J. C., Beutler E., Brittenham G., Buchanan A. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA. 1998 Jul 8;280(2):172–178. doi: 10.1001/jama.280.2.172. [DOI] [PubMed] [Google Scholar]
  8. Carter R., Glasziou P., van Oortmarssen G., de Koning H., Stevenson C., Salkeld G., Boer R. Cost-effectiveness of mammographic screening in Australia. Aust J Public Health. 1993 Mar;17(1):42–50. doi: 10.1111/j.1753-6405.1993.tb00103.x. [DOI] [PubMed] [Google Scholar]
  9. Crawford D. H., Jazwinska E. C., Cullen L. M., Powell L. W. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology. 1998 May;114(5):1003–1008. doi: 10.1016/s0016-5085(98)70320-8. [DOI] [PubMed] [Google Scholar]
  10. DudokdeWit A. C., Tibben A., Duivenvoorden H. J., Niermeijer M. F., Passchier J., Trijsburg R. W. Distress in individuals facing predictive DNA testing for autosomal dominant late-onset disorders: comparing questionnaire results with in-depth interviews. Rotterdam/Leiden Genetics Workgroup. Am J Med Genet. 1998 Jan 6;75(1):62–74. doi: 10.1002/(sici)1096-8628(19980106)75:1<62::aid-ajmg14>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  11. Feder J. N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D. A., Basava A., Dormishian F., Domingo R., Jr, Ellis M. C., Fullan A. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996 Aug;13(4):399–408. doi: 10.1038/ng0896-399. [DOI] [PubMed] [Google Scholar]
  12. Feder J. N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D. A., Basava A., Dormishian F., Domingo R., Jr, Ellis M. C., Fullan A. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996 Aug;13(4):399–408. doi: 10.1038/ng0896-399. [DOI] [PubMed] [Google Scholar]
  13. George D. K., Goldwurm S., MacDonald G. A., Cowley L. L., Walker N. I., Ward P. J., Jazwinska E. C., Powell L. W. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. 1998 Feb;114(2):311–318. doi: 10.1016/s0016-5085(98)70482-2. [DOI] [PubMed] [Google Scholar]
  14. Hudson K. L., Rothenberg K. H., Andrews L. B., Kahn M. J., Collins F. S. Genetic discrimination and health insurance: an urgent need for reform. Science. 1995 Oct 20;270(5235):391–393. doi: 10.1126/science.270.5235.391. [DOI] [PubMed] [Google Scholar]
  15. Jouanolle A. M., Fergelot P., Gandon G., Yaouanq J., Le Gall J. Y., David V. A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. Hum Genet. 1997 Oct;100(5-6):544–547. doi: 10.1007/s004390050549. [DOI] [PubMed] [Google Scholar]
  16. Leggett B. A., Halliday J. W., Brown N. N., Bryant S., Powell L. W. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol. 1990 Apr;74(4):525–530. doi: 10.1111/j.1365-2141.1990.tb06345.x. [DOI] [PubMed] [Google Scholar]
  17. Lench N., Stanier P., Williamson R. Simple non-invasive method to obtain DNA for gene analysis. Lancet. 1988 Jun 18;1(8599):1356–1358. doi: 10.1016/s0140-6736(88)92178-2. [DOI] [PubMed] [Google Scholar]
  18. Morris M. J., Tyler A., Lazarou L., Meredith L., Harper P. S. Problems in genetic prediction for Huntington's disease. Lancet. 1989 Sep 9;2(8663):601–603. doi: 10.1016/s0140-6736(89)90721-6. [DOI] [PubMed] [Google Scholar]
  19. Piperno A., Sampietro M., Pietrangelo A., Arosio C., Lupica L., Montosi G., Vergani A., Fraquelli M., Girelli D., Pasquero P. Heterogeneity of hemochromatosis in Italy. Gastroenterology. 1998 May;114(5):996–1002. doi: 10.1016/s0016-5085(98)70319-1. [DOI] [PubMed] [Google Scholar]
  20. Powell L. W., Bassett M. L. Haemochromatosis: diagnosis and management after the cloning of the HFE gene. Aust N Z J Med. 1998 Apr;28(2):159–163. doi: 10.1111/j.1445-5994.1998.tb02964.x. [DOI] [PubMed] [Google Scholar]
  21. Powell L. W. Hemochromatosis: the impact of early diagnosis and therapy. Gastroenterology. 1996 Apr;110(4):1304–1307. doi: 10.1053/gast.1996.v110.agast961304. [DOI] [PubMed] [Google Scholar]
  22. Williamson R. Universal community carrier screening for cystic fibrosis? Nat Genet. 1993 Mar;3(3):195–201. doi: 10.1038/ng0393-195. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Ethics are provided here courtesy of BMJ Publishing Group

RESOURCES